Abstract:BACKGROUND AND OBJECTIVES:Identification of individuals at high risk of developing Parkinson disease (PD) several years before diagnosis is crucial for developing treatments to prevent or delay neurodegeneration. This study aimed to develop predictive models for PD risk that combine plasma proteins and easily accessible clinical-demographic variables. METHODS:Using data from the UK Biobank (UKB), which recruited participants across the United Kingdom, we conducted a longitudinal study to identify predictors for incident PD. Participants with baseline plasma proteins and no PD were included. Through machine learning, we narrowed down predictors from a pool of 1,463 plasma proteins and 93 clinical-demographic. These predictors were then externally validated using the Parkinson's Progression Marker Initiative (PPMI) cohort. To further investigate the temporal trends of predictors, a nested case-control study was conducted within the UKB. RESULTS:A total of 52,503 participants without PD (median age 58, 54% female) were included. Over a median follow-up duration of 14.0 years, 751 individuals were diagnosed with PD (median age 65, 37% female). Using a forward selection approach, we selected a panel of 22 plasma proteins for optimal prediction. Using an ensemble tree-based Light Gradient Boosting Machine (LightGBM) algorithm, the model achieved an area under the receiver operating characteristic curve (AUC) of 0.800 (95% CI 0.785-0.815). The LightGBM prediction model integrating both plasma proteins and clinical-demographic variables demonstrated enhanced predictive accuracy, with an AUC of 0.832 (95% CI 0.815-0.849). Key predictors identified included age, years of education, history of traumatic brain injury, and serum creatinine. The incorporation of 11 plasma proteins (neurofilament light, integrin subunit alpha V, hematopoietic PGD synthase, histamine N-methyltransferase, tubulin polymerization promoting protein family member 3, ectodysplasin A2 receptor, Latexin, interleukin-13 receptor subunit alpha-1, BAG family molecular chaperone regulator 3, tryptophanyl-TRNA synthetase, and secretogranin-2) augmented the model's predictive accuracy. External validation in the PPMI cohort confirmed the model's reliability, producing an AUC of 0.810 (95% CI 0.740-0.873). Notably, alterations in these predictors were detectable several years before the diagnosis of PD. DISCUSSION:Our findings support the potential utility of a machine learning-based model integrating clinical-demographic variables with plasma proteins to identify individuals at high risk for PD within the general population. Although these predictors have been validated by PPMI, additional validation in a more diverse population reflective of the general community is essential.

Development and Validation of a Plasma FAM19A5 and MRI-Based Radiomics Model for Prediction of Parkinson’s Disease and Parkinson’s Disease With Depression

Contribution and Clinical Significance of 3D and 2D Deep Learning and Radimoics Features Based on MR-T1W Images in Joint Diagnosis of Parkinson's Disease

An Integrative Nomogram for Identifying Early-Stage Parkinson's Disease Using Non-motor Symptoms and White Matter-Based Radiomics Biomarkers from Whole-Brain MRI

Predicting the progression of Parkinson's disease using conventional MRI and machine learning: An application of radiomic biomarkers in whole-brain white matter

An Automated Hybrid Approach Via Deep Learning and Radiomics Focused on the Midbrain and Substantia Nigra to Detect Early-Stage Parkinson’s Disease

Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis

A Multiple-Tissue-specific Magnetic Resonance Imaging Model for Diagnosing Parkinson's Disease: a Brain Radiomics Study.

A Radiomics Approach to Predicting Parkinson’s Disease by Incorporating Whole-Brain Functional Activity and Gray Matter Structure

Aberrant functional connectivity and activity in Parkinson's disease and comorbidity with depression based on radiomic analysis

Diffusion Tensor Imaging Radiomics for Diagnosis of Parkinson's Disease

Prediction of Future Parkinson Disease Using Plasma Proteins Combined with Clinical-Demographic Measures

Use of radiomic features and support vector machine to distinguish Parkinson's disease cases from normal controls

Substantia Nigra Radiomics Feature Extraction of Parkinson’s Disease Based on Magnitude Images of Susceptibility-Weighted Imaging

Use of deep learning-based radiomics to differentiate Parkinson’s disease patients from normal controls: a study based on [ 18 F]FDG PET imaging

Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson's Disease

Plasma derived phosphoglycerate mutase 5 (PGAM5) as a biomarker for Parkinson’s disease

Mir-218-5p and Mir-320A-5p As Biomarkers for Brain Disorders: Focus on the Major Depressive Disorder and Parkinson's Disease.

Multivariate radiomics models based on 18F-FDG hybrid PET/MRI for distinguishing between Parkinson's disease and multiple system atrophy

Converging Mediators from Immune and Trophic Pathways to Identify Parkinson Disease Dementia.

Functional and Structural Alterations As Diagnostic Imaging Markers for Depression in De Novo Parkinson’s Disease

Combined Diffusion Tensor Imaging and Arterial Spin Labeling as Markers of Early Parkinson’s disease